Journal d'immunologie clinique et cellulaire
Libre accès

Abstrait

Therapeutic Targeting of the Cancer-Specific Cell Surface Biomarker nfP2X₇

Julian A Barden, Angus Gidley-Baird, Liew Cheng Teh, G-Halli Rajasekariah, John Pedersen, Neil I Christensen, Derek Spielman and David M Ashley

The degree of unmet need for new therapeutics in oncology is clear since about 30% of the population die from cancer with enormous associated costs in health care and in personal impact. New and preferably specific targets are needed now to address the problem, both to improve overall survival and importantly to reduce side effects in order to improve quality of life. nfP2X7 is a receptor that, unlike P2X7, cannot enable apoptosis in cancer cells. Having established the widespread coverage of human cancers in which the aberrant receptor is found, attention has been drawn to the therapeutic potential of the target and whether an immunotherapeutic approach is capable of providing a significant therapeutic response. We demonstrate the intrinsic target specificity, the delivery of antibody within target cells, the extremely good safety profile of the targeting antibody and the broad range of cancer tissue that could be treated in both humans and other animals.